DRNA
$16.39
Dicerna Pharmaceutic
$.59
3.73%
DRNA
Earnings Whisper ®
N/A
3rd Quarter September 2019
Consensus:  ($0.29)
Revenue:  $11.70 Mil
Monday
Nov 4
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when DRNA reports earnings?
Beat
Meet
Miss

Where is DRNA's stock price going from here?
Up
Flat
Down
Stock chart of DRNA
Analysts
Summary of analysts' recommendations for DRNA
Score
Grade
Pivots
Resistance
$17.54
$17.03
$16.71

$16.20

Support
$15.88
$15.37
$15.05
Tweet
Growth
Description
Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
Peers
IncyteAlexion PharmaceuticalsExact SciencesCharles River Laboratories InternationalExelixisCoherus BiosciencesLuminex